Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 2, Randomized, Open-label, Multicenter Study to Evaluate Efficacy, Pharmacokinetics, Safety, and Tolerability of Treatment With JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)ide Analog With or Without JNJ-56136379 in Treatment-naïve Patients With HBeAg Positive Chronic Hepatitis B Virus Infection

    Summary
    EudraCT number
    2019-004978-26
    Trial protocol
    GB   FR   DE  
    Global end of trial date
    12 Feb 2024

    Results information
    Results version number
    v1(current)
    This version publication date
    17 Apr 2025
    First version publication date
    17 Apr 2025
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    73763989PAHPB2005
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT04439539
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Janssen Research & Development, LLC
    Sponsor organisation address
    920 Route 202, Raritan, United States, 08869
    Public contact
    Clinical Registry Group, Janssen Research & Development, LLC, ClinicalTrialsEU@its.jnj.com
    Scientific contact
    Clinical Registry Group, Janssen Research & Development, LLC, ClinicalTrialsEU@its.jnj.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    12 Feb 2024
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    12 Feb 2024
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The main objective of the study was to assess the efficacy of a treatment regimen of JNJ-73763989 (JNJ-3989) plus pegylated interferon alpha-2a (PegIFN-alpha-2a) plus nucleos(t)ide analog (NA: tenofovir disoproxil [TDF]/tenofovir alafenamide [TAF]).
    Protection of trial subjects
    This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    15 Oct 2020
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Canada: 7
    Country: Number of subjects enrolled
    Germany: 2
    Country: Number of subjects enrolled
    Spain: 8
    Country: Number of subjects enrolled
    France: 6
    Country: Number of subjects enrolled
    United Kingdom: 5
    Country: Number of subjects enrolled
    Japan: 4
    Country: Number of subjects enrolled
    Russian Federation: 10
    Country: Number of subjects enrolled
    Türkiye: 9
    Country: Number of subjects enrolled
    Taiwan: 2
    Country: Number of subjects enrolled
    United States: 1
    Worldwide total number of subjects
    54
    EEA total number of subjects
    16
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    54
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The Study consisted of 3 phases: induction phase (IP), consolidation phase (CP) and follow-up (FU) phase. Response-guided treatment (RGT): hepatitis B (HB) surface antigen (HBsAg) less than(<) 10 international unit per millilitre (IU/mL ) and RGT was removed post protocol amanedment 5 (PA 5).

    Pre-assignment
    Screening details
    Nucleos(t)ide (NA) treatment completion criteria: HBsAg <10 IU/mL, HB envelop antigen (HBeAg)-negative, HB virus deoxyribonucleic acid (HBV DNA) <lower limit of quantification (LLOQ) and alanine aminotransferase (ALT) <3*upper limit of normal (ULN).

    Period 1
    Period 1 title
    IP:Day 1-Week 36(post-PA5)/52(prior-PA5)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a
    Arm description
    Prior to PA 5, in IP, enrolled participants received JNJ-3989 200 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) + JNJ-6379 250 mg tablets orally once daily (QD) + NA (TDF 245 mg/TAF 25 mg) tablet orally QD for >=36 to <=52 weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Post PA 5, participant not reached IP Week 36, started PegINF-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at their next visit. Per PA 6, JNJ-6379 treatment was stopped. Post CP Week 12, participants entered 48-week FU phase and stopped JNJ-3989+PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.
    Arm type
    Experimental

    Investigational medicinal product name
    JNJ-73763989
    Investigational medicinal product code
    JNJ-73763989
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Participants received JNJ-3989 200 mg SC injection Q4W for >=36-weeks (post PA 5) to <=52-weeks (prior to PA 5)

    Investigational medicinal product name
    Tenofovir alafenamide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Participants received TAF 25 mg tablet orally QD for up to >=36-weeks (post PA 5) to <=52-weeks (prior to PA 5)

    Investigational medicinal product name
    Tenofovir disoproxil
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Participants received TAD 245 mg tablet orally QD for up to >=36-weeks (post PA 5) to <=52-weeks (prior to PA 5)

    Investigational medicinal product name
    JNJ-56136379
    Investigational medicinal product code
    JNJ-56136379
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Participants received JNJ-6379 250 mg tablet orally QD for >=36-weeks (post PA 5) to <=52-weeks (prior to PA 5)

    Arm title
    Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a
    Arm description
    Per PA 5, in the IP, enrolled participants received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegINF-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment withJNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.
    Arm type
    Experimental

    Investigational medicinal product name
    JNJ-73763989
    Investigational medicinal product code
    JNJ-73763989
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Participants received JNJ-3989 200 mg SC injection Q4W for 36 weeks.

    Investigational medicinal product name
    Tenofovir alafenamide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Participants received TAF 25 mg tablet orally QD for 36 weeks.

    Investigational medicinal product name
    Tenofovir disoproxil
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Participants received TAD 245 mg tablet orally QD for 36 weeks.

    Arm title
    Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a
    Arm description
    In the IP, participants enrolled as per PA 6 received JNJ-3989 200 mg SC injection Q4W plus NA (TDF 245 mg/TAF 25 mg) tablet orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegIFN-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.
    Arm type
    Experimental

    Investigational medicinal product name
    JNJ-73763989
    Investigational medicinal product code
    JNJ-73763989
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Participants received JNJ-3989 200 mg SC injection Q4W for 36 weeks.

    Investigational medicinal product name
    Tenofovir alafenamide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Participants received TAF 25 mg tablet orally QD for 36 weeks.

    Investigational medicinal product name
    Tenofovir disoproxil
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Participants received TAD 245 mg tablet orally QD for 36 weeks.

    Number of subjects in period 1
    Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a
    Started
    27
    8
    19
    Completed
    26
    8
    17
    Not completed
    1
    0
    2
         Consent withdrawn by subject
    1
    -
    2
    Period 2
    Period 2 title
    CP Phase: CP Week 1 to 12
    Is this the baseline period?
    No
    Allocation method
    Randomised - controlled
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a
    Arm description
    Prior to PA 5, in IP, enrolled participants received JNJ-3989 200 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) + JNJ-6379 250 mg tablets orally once daily (QD) + NA (TDF 245 mg/TAF 25 mg) tablet orally QD for >=36 to <=52 weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Post PA 5, participant not reached IP Week 36, started PegINF-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at their next visit. Per PA 6, JNJ-6379 treatment was stopped. Post CP Week 12, participants entered 48-week FU phase and stopped JNJ-3989+PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.
    Arm type
    Experimental

    Investigational medicinal product name
    JNJ-73763989
    Investigational medicinal product code
    JNJ-73763989
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Participants received JNJ-3989 200 mg SC injection Q4W from CP Week 1 to 12.

    Investigational medicinal product name
    JNJ-56136379
    Investigational medicinal product code
    JNJ-56136379
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Participants received JNJ-6379 250 mg tablet orally QD from CP Week 1 to 12.

    Investigational medicinal product name
    pegylated interferon alpha-2a
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Participants received PegIFN-alpha-2a 180 mcg SC injection QW from IP Week 36 for 12 weeks. Those who passed IP W36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a from their next visit up to CP Week 12.

    Investigational medicinal product name
    Tenofovir alafenamide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Participants received TAF 25 mg tablet orally QD from CP Week 1 to 12.

    Investigational medicinal product name
    Tenofovir disoproxil
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Participants received TAD 245 mg tablet orally QD from CP Week 1 to 12.

    Arm title
    Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a
    Arm description
    Per PA 5, in the IP, enrolled participants received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegINF-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment withJNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.
    Arm type
    Experimental

    Investigational medicinal product name
    JNJ-73763989
    Investigational medicinal product code
    JNJ-73763989
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Participants received JNJ-3989 200 mg SC injection Q4W from CP Week 1 to 12.

    Investigational medicinal product name
    pegylated interferon alpha-2a
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Participants received PegIFN-alpha-2a 180 mcg SC injection QW from IP Week 36 for 12 weeks. Those who passed IP W36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a from their next visit up to CP Week 12.

    Investigational medicinal product name
    Tenofovir alafenamide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Participants received TAF 25 mg tablet orally QD from CP Week 1 to 12.

    Investigational medicinal product name
    Tenofovir disoproxil
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Participants received TAD 245 mg tablet orally QD from CP Week 1 to 12.

    Arm title
    Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a
    Arm description
    In the IP, participants enrolled as per PA 6 received JNJ-3989 200 mg SC injection Q4W plus NA (TDF 245 mg/TAF 25 mg) tablet orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegIFN-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.
    Arm type
    Experimental

    Investigational medicinal product name
    JNJ-73763989
    Investigational medicinal product code
    JNJ-73763989
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Participants received JNJ-3989 200 mg SC injection Q4W from CP Week 1 to 12.

    Investigational medicinal product name
    pegylated interferon alpha-2a
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Participants received PegIFN-alpha-2a 180 mcg SC injection QW from IP Week 36 for 12 weeks. Those who passed IP W36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a from their next visit up to CP Week 12.

    Investigational medicinal product name
    Tenofovir alafenamide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Participants received TAF 25 mg tablet orally QD from CP Week 1 to 12.

    Investigational medicinal product name
    Tenofovir disoproxil
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Participants received TAD 245 mg tablet orally QD from CP Week 1 to 12.

    Number of subjects in period 2
    Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a
    Started
    26
    8
    17
    Subjects actually started CP
    25 [1]
    7 [2]
    17
    Completed
    26
    8
    17
    Notes
    [1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
    Justification: One participant discontinued JNJ-3989 treatment due to treatment failure/relapse and moved directly from IP to FU phase without CP.
    [2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
    Justification: One participant discontinued JNJ-3989 treatment due to treatment failure/relapse and moved directly from IP to FU phase without CP.
    Period 3
    Period 3 title
    FU Phase: FU Week 1 to 48
    Is this the baseline period?
    No
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a
    Arm description
    Prior to PA 5, in IP, enrolled participants received JNJ-3989 200 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) + JNJ-6379 250 mg tablets orally once daily (QD) + NA (TDF 245 mg/TAF 25 mg) tablet orally QD for >=36 to <=52 weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Post PA 5, participant not reached IP Week 36, started PegINF-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at their next visit. Per PA 6, JNJ-6379 treatment was stopped. Post CP Week 12, participants entered 48-week FU phase and stopped JNJ-3989+PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.
    Arm type
    Experimental

    Investigational medicinal product name
    Tenofovir alafenamide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Participants received TAF 25 mg tablet orally QD up to FU Week 2. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU Week 2. If NA completion criteria was not met, NA was continued till the end of FU phase (FU Week 48).

    Investigational medicinal product name
    Tenofovir disoproxil
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Participants received TDF 245 mg tablet orally QD up to FU Week 2. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU Week 2. If NA completion criteria was not met, NA was continued till the end of FU phase (FU Week 48).

    Arm title
    Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a
    Arm description
    Per PA 5, in the IP, enrolled participants received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegINF-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment withJNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.
    Arm type
    Experimental

    Investigational medicinal product name
    Tenofovir alafenamide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Participants received TAF 25 mg tablet orally QD up to FU Week 2. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU Week 2. If NA completion criteria was not met, NA was continued till the end of FU phase (FU Week 48).

    Investigational medicinal product name
    Tenofovir disoproxil
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Participants received TDF 245 mg tablet orally QD up to FU Week 2. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU Week 2. If NA completion criteria was not met, NA was continued till the end of FU phase (FU Week 48).

    Arm title
    Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a
    Arm description
    In the IP, participants enrolled as per PA 6 received JNJ-3989 200 mg SC injection Q4W plus NA (TDF 245 mg/TAF 25 mg) tablet orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegIFN-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.
    Arm type
    Experimental

    Investigational medicinal product name
    Tenofovir alafenamide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Participants received TAF 25 mg tablet orally QD up to FU Week 2. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU Week 2. If NA completion criteria was not met, NA was continued till the end of FU phase (FU Week 48).

    Investigational medicinal product name
    Tenofovir disoproxil
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Participants received TDF 245 mg tablet orally QD up to FU Week 2. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU Week 2. If NA completion criteria was not met, NA was continued till the end of FU phase (FU Week 48).

    Number of subjects in period 3
    Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a
    Started
    26
    8
    17
    Completed
    26
    6
    17
    Not completed
    0
    2
    0
         Consent withdrawn by subject
    -
    1
    -
         Unspecified
    -
    1
    -

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a
    Reporting group description
    Prior to PA 5, in IP, enrolled participants received JNJ-3989 200 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) + JNJ-6379 250 mg tablets orally once daily (QD) + NA (TDF 245 mg/TAF 25 mg) tablet orally QD for >=36 to <=52 weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Post PA 5, participant not reached IP Week 36, started PegINF-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at their next visit. Per PA 6, JNJ-6379 treatment was stopped. Post CP Week 12, participants entered 48-week FU phase and stopped JNJ-3989+PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.

    Reporting group title
    Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a
    Reporting group description
    Per PA 5, in the IP, enrolled participants received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegINF-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment withJNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.

    Reporting group title
    Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a
    Reporting group description
    In the IP, participants enrolled as per PA 6 received JNJ-3989 200 mg SC injection Q4W plus NA (TDF 245 mg/TAF 25 mg) tablet orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegIFN-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.

    Reporting group values
    Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a Total
    Number of subjects
    27 8 19
    Age Categorical
    Units: Subjects
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    35.6 ( 9.95 ) 27.3 ( 9.95 ) 33.6 ( 11.15 ) -
    Gender categorical
    Units: Subjects
        Male
    12 5 11 28
        Female
    15 3 8 26

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a
    Reporting group description
    Prior to PA 5, in IP, enrolled participants received JNJ-3989 200 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) + JNJ-6379 250 mg tablets orally once daily (QD) + NA (TDF 245 mg/TAF 25 mg) tablet orally QD for >=36 to <=52 weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Post PA 5, participant not reached IP Week 36, started PegINF-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at their next visit. Per PA 6, JNJ-6379 treatment was stopped. Post CP Week 12, participants entered 48-week FU phase and stopped JNJ-3989+PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.

    Reporting group title
    Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a
    Reporting group description
    Per PA 5, in the IP, enrolled participants received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegINF-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment withJNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.

    Reporting group title
    Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a
    Reporting group description
    In the IP, participants enrolled as per PA 6 received JNJ-3989 200 mg SC injection Q4W plus NA (TDF 245 mg/TAF 25 mg) tablet orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegIFN-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.
    Reporting group title
    Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a
    Reporting group description
    Prior to PA 5, in IP, enrolled participants received JNJ-3989 200 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) + JNJ-6379 250 mg tablets orally once daily (QD) + NA (TDF 245 mg/TAF 25 mg) tablet orally QD for >=36 to <=52 weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Post PA 5, participant not reached IP Week 36, started PegINF-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at their next visit. Per PA 6, JNJ-6379 treatment was stopped. Post CP Week 12, participants entered 48-week FU phase and stopped JNJ-3989+PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.

    Reporting group title
    Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a
    Reporting group description
    Per PA 5, in the IP, enrolled participants received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegINF-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment withJNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.

    Reporting group title
    Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a
    Reporting group description
    In the IP, participants enrolled as per PA 6 received JNJ-3989 200 mg SC injection Q4W plus NA (TDF 245 mg/TAF 25 mg) tablet orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegIFN-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.
    Reporting group title
    Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a
    Reporting group description
    Prior to PA 5, in IP, enrolled participants received JNJ-3989 200 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) + JNJ-6379 250 mg tablets orally once daily (QD) + NA (TDF 245 mg/TAF 25 mg) tablet orally QD for >=36 to <=52 weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Post PA 5, participant not reached IP Week 36, started PegINF-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at their next visit. Per PA 6, JNJ-6379 treatment was stopped. Post CP Week 12, participants entered 48-week FU phase and stopped JNJ-3989+PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.

    Reporting group title
    Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a
    Reporting group description
    Per PA 5, in the IP, enrolled participants received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegINF-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment withJNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.

    Reporting group title
    Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a
    Reporting group description
    In the IP, participants enrolled as per PA 6 received JNJ-3989 200 mg SC injection Q4W plus NA (TDF 245 mg/TAF 25 mg) tablet orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegIFN-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.

    Subject analysis set title
    Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Prior PA 5, participants received JNJ-3989 200 mg SC injection 4th weekly(Q4W) + JNJ-6379 250 mg tablets orally once daily (QD) + NA (TDF 245 mg/TAF 25 mg) tablet orally QD in IP for >=36 to <=60 weeks. Participants who met RGT criterion or reached 60 weeks were considered completed IP & entered 12 week CP & randomized to JNJ-3989 200 mg SC injection Q4W + JNJ-6379 250 mg tablets orally QD + NA (TDF 245 mg/TAF 25 mg) tablet orally QD or JNJ-3989 200 mg SC injection Q4W + JNJ-6379 250 mg tablets orally QD + NA (TDF 245 mg/TAF 25 mg) tablets orally QD + PegIFN-alpha-2a 180 mcg SC injection QW. Post PA 5, participants not reached IP Week (W)36, started PegINF-alpha-2a at W36 for 12 weeks & who passed IP W36 &/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at next visit. Per PA 6 JNJ-6379 treatment discontinued. Post 12 week CP, participants entered 48 week FU phase till FU Week 48 & stopped JNJ-3989 + PegIFN-alpha-2a.

    Subject analysis set title
    Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Per PA 5, participants in IP received JNJ-3989 200 mg SC injection for Q4W plus NA (tenofovir disoproxil 245 mg/tenofovir alafenamide 25 mg) tablets orally QD for 36 weeks. After completion of IP W36, all participants entered 12-week CP during which PegINF-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, all participants entered the 48-week FU phase and stopped treatment withJNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP W12 NA was stopped at FU W2, if completion criteria was not met NAwas continued till the end of FU phase.

    Subject analysis set title
    Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants enrolled as per PA 6 received JNJ-3989 200 mg SC injection for Q4W plus NA (tenofovir disoproxil 245 mg/tenofovir alafenamide 25 mg) tablet orally QD for 36 weeks in IP. After completion of IP, participants entered 12-week CP and received PegIFN-alpha-2a 180 mcg QW for 12-week. Aftcompletion of 12-week CP, all participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus NA plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP W12 NA was stopped at FU W2, if completion criteria was not met NA was continued till the end of FU phase

    Subject analysis set title
    IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Prior to PA 5, participants received JNJ-3989 200 mg SC injection for Q4W + JNJ-6379 250 mg tablets orally QD plus NA (TAD 245 mg/TAF 25 mg) tablet orally QD in IP for a RGT duration for >=36-weeks to <=52-weeks.

    Subject analysis set title
    IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Per PA 5, participants received JNJ-3989 200 mg SC injection for Q4W plus NA (TAD 245 mg/TAF 25 mg) tablets orally QD in IP for 36 weeks.

    Subject analysis set title
    IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants enrolled as per PA 6, received JNJ-3989 200 mg SC for Q4W plus NA (TAD 250 mg/TAF 25 mg) tablet orally QD in IP for 36 weeks.

    Subject analysis set title
    CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a
    Subject analysis set type
    Per protocol
    Subject analysis set description
    After completion of IP, participants entered in 12 week CP and received JNJ-3989 200 mg SC Q4W plus JNJ-6379 250 tablets QD plus NA (either TAD 250 mg or TAF 25 mg) tablet orally QD from CP Week 1 to 12 and PegIFN-alpha-2a 180 mcg SC injection was added to their treatment regimen from IP Week 36 for 12 weeks.

    Subject analysis set title
    CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a
    Subject analysis set type
    Per protocol
    Subject analysis set description
    After completion of IP, participants entered in 12-week CP and received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD from CP Week 1 to 12 and PegIFN-alpha2a 180 mcg SC QW was added to their treatment regimen from IP Week 36 for 12 weeks.

    Subject analysis set title
    CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Subject analysis set type
    Per protocol
    Subject analysis set description
    After completion of IP, participants entered in 12-week CP and received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD from CP Week 1 to 12 and PegIFN-alpha2a 180 mcg SC QW was added to their treatment regimen from IP Week 36 for 12 weeks.

    Subject analysis set title
    FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a
    Subject analysis set type
    Per protocol
    Subject analysis set description
    After completion of CP, all participants entered 48-Week FU phase and stopped treatment with JNJ-3989 plus JNJ-6379 plus NA (TAD 245 mg/TAF 25 mg) plus PegIFN-alpha2a. If NA treatment completion criteria was met at CP Week 12 NA was stopped at FU W2, if NA treatment completion criteria was not met, NA (TAD 245 mg/TAF 25 mg) was continued till the end of FU phase.

    Subject analysis set title
    FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a
    Subject analysis set type
    Per protocol
    Subject analysis set description
    After completion of CP, all participants entered 48-Week FU phase and stopped treatment with JNJ-3989 plus NA (TAD 245 mg/TAF 25 mg) plus PegIFN-alpha2a. If NA treatment completion criteria was met at CP Week 12, NA treatment was stopped at FU Week 2, if NA treatment completion criteria was not met, NA (TAD 245 mg/TAF 25 mg) was continued till the end of FU phase.

    Subject analysis set title
    FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Subject analysis set type
    Per protocol
    Subject analysis set description
    After completion of CP, all participants entered 48-Week FU phase and stopped treatment with JNJ-3989 plus NA (TAD 245 mg/TAF 25 mg) plus PegIFN-alpha2a. If NA treatment completion criteria was met at CP Week 12, NA treatment was stopped at FU Week 2, if NA treatment completion criteria was not met, NA (TAD 245 mg/TAF 25 mg) was continued till the end of FU phase.

    Subject analysis set title
    Induction phase
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Prior PA 5, participants received JNJ-3989 200 mg SC injection for Q4W + JNJ-6379 250 mg tablets orally QD plus NA (TAD 245 mg/TAF 25 mg) tablet orally QD for >=36-weeks to <=52-weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Per PA 5, participants received JNJ-3989 200 mg SC injection for Q4W plus NA (TAD 245 mg/TAF 25 mg) tablets orally QD for 36 weeks. Participants enrolled as per PA 6, received JNJ-3989 200 mg SC for Q4W plus NA (either tenofovir disoproxil 250 mg or 25 mg tenofovir alafenamide) tablet orally QD for 36 weeks in IP. Post PA 5, participant not reached IP Week 36, started PegINF-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at their next visit.

    Subject analysis set title
    Consolidation phase
    Subject analysis set type
    Per protocol
    Subject analysis set description
    After completion of IP, participants entered the 12 weeks CP and received JNJ-3989 200 mg SC Q4W plus JNJ-6379 250 tablets QD plus NA (either TDF 245 mg/TAF 25 mg) tablet orally QD plus PegIFN-alpha-2a 180 mcg SC QW. At the end of the CP, all participants entered the 48-weeks follow-up (FU) phase and stopped treatment with JNJ-3989 plus JNJ-6379 plus NA plus PegIFN-alpha-2a.If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.

    Subject analysis set title
    Induction phase
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Prior PA 5, participants received JNJ-3989 200 mg SC injection for Q4W + JNJ-6379 250 mg tablets orally QD plus NA (TAD 245 mg/TAF 25 mg) tablet orally QD for >=36-weeks to <=52-weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Per PA 5, participants received JNJ-3989 200 mg SC injection for Q4W plus NA (TAD 245 mg/TAF 25 mg) tablets orally QD for 36 weeks. Participants enrolled as per PA 6, received JNJ-3989 200 mg SC for Q4W plus NA (either tenofovir disoproxil 250 mg or 25 mg tenofovir alafenamide) tablet orally QD for 36 weeks in IP. Post PA 5, participant not reached IP Week 36, started PegINF-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at their next visit.

    Subject analysis set title
    Consolidation phase
    Subject analysis set type
    Per protocol
    Subject analysis set description
    After completion of IP, participants entered the 12 weeks CP and received JNJ-3989 200 mg SC Q4W plus JNJ-6379 250 tablets QD plus NA (either TDF 245 mg/TAF 25 mg) tablet orally QD plus PegIFN-alpha-2a 180 mcg SC QW. At the end of the CP, all participants entered the 48-weeks follow-up (FU) phase and stopped treatment with JNJ-3989 plus JNJ-6379 plus NA plus PegIFN-alpha-2a.If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.

    Subject analysis set title
    Induction phase
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Prior PA 5, participants received JNJ-3989 200 mg SC injection for Q4W + JNJ-6379 250 mg tablets orally QD plus NA (TAD 245 mg/TAF 25 mg) tablet orally QD for >=36-weeks to <=52-weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Per PA 5, participants received JNJ-3989 200 mg SC injection for Q4W plus NA (TAD 245 mg/TAF 25 mg) tablets orally QD for 36 weeks. Participants enrolled as per PA 6, received JNJ-3989 200 mg SC for Q4W plus NA (either tenofovir disoproxil 250 mg or 25 mg tenofovir alafenamide) tablet orally QD for 36 weeks in IP. Post PA 5, participant not reached IP Week 36, started PegINF-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at their next visit.

    Subject analysis set title
    Consolidation phase
    Subject analysis set type
    Per protocol
    Subject analysis set description
    After completion of IP, participants entered the 12 weeks CP and received JNJ-3989 200 mg SC Q4W plus JNJ-6379 250 tablets QD plus NA (either TDF 245 mg/TAF 25 mg) tablet orally QD plus PegIFN-alpha-2a 180 mcg SC QW. At the end of the CP, all participants entered the 48-weeks follow-up (FU) phase and stopped treatment with JNJ-3989 plus JNJ-6379 plus NA plus PegIFN-alpha-2a.If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.

    Primary: Percentage of Participants With Functional Cure: Hepatitis B Surface Antigen (HBsAg) Seroclearance at 24 Weeks After Stopping all Study Interventions at the end of Consolidation Phase (CP) and Without Restarting Nucleos(t)ide analog (NA) Treatment

    Close Top of page
    End point title
    Percentage of Participants With Functional Cure: Hepatitis B Surface Antigen (HBsAg) Seroclearance at 24 Weeks After Stopping all Study Interventions at the end of Consolidation Phase (CP) and Without Restarting Nucleos(t)ide analog (NA) Treatment [1]
    End point description
    Percentage of participants with functional cure (defined as percentage of participants with HBsAg seroclearance at 24 weeks after stopping all study interventions at end of CP and without restarting NA treatment) were reported. Seroclearance of HBsAg was defined as a (quantitative) HBsAg level less than (<) lower limit of quantification (LLOQ; 0.05 IU/mL). Per protocol analysis set: all randomised/enrolled participants who received at least 1 dose of CP study intervention and did not had any of the selected major protocol deviations that might affect the assessment of efficacy in terms of the primary endpoint at 24 weeks after stopping all study interventions of the CP.
    End point type
    Primary
    End point timeframe
    At follow-up (FU) phase Week 24
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No inferential statistics was done. Only descriptive statistics was performed.
    End point values
    Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a
    Number of subjects analysed
    26
    8
    17
    Units: percentage of participants
        number (not applicable)
    0
    0
    0
    No statistical analyses for this end point

    Secondary: Number of Participants with Treatment Emergent Adverse Events (TEAEs)

    Close Top of page
    End point title
    Number of Participants with Treatment Emergent Adverse Events (TEAEs)
    End point description
    Number of participants with TEAEs were reported. An adverse event (AE) was any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the study intervention. Treatment-emergent AEs are all AEs with an onset on or after the first administration of study treatment or any ongoing event that worsened in severity, intensity or frequency after the first administration of study treatment. Safety analysis set (SAS) included all participants who received at least one dose of study intervention. Participants were analysed according to the study intervention they actually received.
    End point type
    Secondary
    End point timeframe
    IP: From Day 1 up to end of IP (up to Week 36 per PA 5; up to Week 52 prior to PA 5); CP: CP Week 1 up to CP Week 12; FU phase: FU Week 1 up to FU Week 48
    End point values
    IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    27
    8
    19
    25 [2]
    7 [3]
    17
    26 [4]
    8 [5]
    17
    Units: participants
    22
    8
    15
    22
    7
    13
    17
    5
    11
    Notes
    [2] - 1 participant who moved directly from IP to FU was not counted in this arm.
    [3] - 1 participant who moved directly from IP to FU was not counted in this arm.
    [4] - 25 participants from CP + 1 participant moved directly from IP.
    [5] - 7 participants from CP + 1 participant moved directly from IP.
    No statistical analyses for this end point

    Secondary: Number of Participants with Treatment Emergent Serious Adverse Events (TESAEs)

    Close Top of page
    End point title
    Number of Participants with Treatment Emergent Serious Adverse Events (TESAEs)
    End point description
    Number of participants with TESAEs were reported. An AE was any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the study intervention. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs are all AEs with an onset on or after the first administration of study treatment or any ongoing event that worsened in severity, intensity or frequency after the first administration of study treatment. Safety analysis set included all participants who received at least one dose of study intervention. Participants were analysed according to the study intervention they actually received.
    End point type
    Secondary
    End point timeframe
    IP: From Day 1 up to end of IP (up to Week 36 per PA 5; up to Week 52 prior to PA 5); CP: CP Week 1 up to CP Week 12; FU phase: FU Week 1 up to FU Week 48
    End point values
    IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    27
    8
    19
    25
    7
    17
    26
    8
    17
    Units: participants
    0
    0
    0
    0
    0
    0
    0
    0
    1
    No statistical analyses for this end point

    Secondary: Number of Participants with Worst (Grade 3 or 4) Treatment-emergent DAIDS Toxicity Grade in Clinical Laboratory Tests

    Close Top of page
    End point title
    Number of Participants with Worst (Grade 3 or 4) Treatment-emergent DAIDS Toxicity Grade in Clinical Laboratory Tests
    End point description
    Laboratory parameters: Hematology (Hem): absolute lymphocyte count, (ALC), A neutrophil count (ANC), hemoglobin (Hb) , Neutrophils Band Form (NBF) , Neutrophils segmented (Neu Seg), WBC decreased (dcrsd); Chem: alanine aminotransferase (ALT) & serum glutamic pyruvic transaminase (SGPT), aspartate aminotransferase(AST)/serum glutamic oxaloacetic transaminase (SGOT), cholesterol (CLSTRL) (fasting[F]), creatinine Kinase (Cr Kin), Glomerular filtration rate (GFR) from Creatinine (Cr) Adjusted for body surface area ((Ad.BSA), GFR Cystatin (Cy) C (Ad. BSA), low-density lipoprotein (LDL: fasting[F]), triglycerides (Tglrds[F]); Urinalysis: glycosuria. DAIDS toxicity grades: Grade (Gr) 1 (Mild), Gr 2 (Moderate), Gr 3 (Severe), Gr 4 (Potentially Life-Threatening). Here, number of participants with TE DAIDS toxicity Grade 3 or 4 were reported in this endpoint. SAS was analysed. n=0, and 99999 signify that data were not collected & analysed as timepoint was not applicable to respective arm.
    End point type
    Secondary
    End point timeframe
    IP: From Day 1 up to end of IP (up to Week 36 per PA 5; up to Week 52 prior to PA 5); CP: CP Week 1 up to CP Week 12; FU phase: FU Week 1 up to FU Week 48
    End point values
    IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    27
    8
    19
    25
    7
    17
    26
    8
    17
    Units: participants
        Hem:ALC:Low:Gr 3 :n=26,8,19, 25,7,17,26,8,17
    0
    0
    0
    1
    0
    0
    0
    0
    0
        Hem: ANC: Gr 3: n=26,8,19, 25,7,17,26,8,17
    0
    0
    0
    2
    0
    0
    0
    0
    0
        Hem: HB: Low: Gr 3 :n=26,8,19, 25,7,17,26,8,17
    0
    0
    0
    1
    0
    0
    0
    1
    0
        Hem: NBF: Low: Gr4:n=0,0,0,3,0,0,1,0,1
    99999
    99999
    99999
    3
    99999
    99999
    1
    99999
    1
        Hem:Neu Seg:Low:Gr3: n=26,8,19,25,7,17,26,8,17
    0
    0
    0
    2
    0
    0
    0
    0
    0
        Hem:WBC dcrsd:Low:Gr3:n=26,8,19,25,7,17,26,8,17
    0
    0
    0
    3
    0
    1
    1
    0
    0
        Chem:ALT/SGPT:High:Gr3:n=26,8,19,25,7,17,26,8,17
    1
    0
    0
    1
    0
    2
    0
    0
    0
        Chem:AST/SGOT:High:Gr3:n=26,8,19,25,7,17,26,8,17
    0
    0
    0
    0
    0
    1
    0
    0
    0
        Chem:CLSTRL(F):High:Gr3:n=26,8,19,25,7,17,26,8,17
    1
    0
    0
    1
    0
    0
    1
    0
    0
        Chem:Cr Kin:High:Gr3:n=26,8,19,25,7,17,26,8,17
    0
    0
    0
    0
    0
    2
    0
    0
    0
        Chem: Cr Kin:High:Gr4:n=26,8,19,25,7,17,26,8,17
    1
    0
    0
    0
    0
    0
    0
    0
    0
        Che:GFR:Cr Ad.BSA:L:Gr3:n=26,8,19,25,7,17,26,8,17
    1
    0
    0
    0
    0
    0
    0
    0
    0
        Che:GFR:Cyc Ad.BSA:L:Gr3:n=26,8,19,25,7,17,26,8,17
    1
    0
    0
    1
    0
    0
    1
    0
    1
        Che:GFR:Cyc Ad.BSA:L:Gr4:n=26,8,19,25,7,17,26,8,17
    0
    0
    0
    0
    0
    0
    0
    0
    1
        Chem:LDL(F):High:Gr3:n=26,8,19,25,7,17,26,8,17
    2
    0
    0
    1
    0
    1
    0
    0
    0
        Chem:Tglrds(F):High:Gr3:n=26,8,19,25,7,17,26,8,17
    0
    0
    1
    1
    0
    0
    1
    0
    0
        Urinalysis:Glycosuria:Gr3:n=17,7,7,13,6,6,12,8,5
    0
    0
    0
    0
    0
    0
    0
    1
    0
    No statistical analyses for this end point

    Secondary: Number of Participants With Worst Treatment-emergent Abnormality in Electrocardiogram (ECGs)

    Close Top of page
    End point title
    Number of Participants With Worst Treatment-emergent Abnormality in Electrocardiogram (ECGs)
    End point description
    Number of participants with worst treatment-emergent abnormality in ECG were reported. Treatment-emergent abnormality was defined as the abnormalities that were worsened as compared to the abnormality at baseline; which also included the shift from abnormally high to abnormally low and vice-versa. ECG parameters included heart rate (HR; abnormally low, HR <45 beats per minute (bpm) and (abnormally high HR>=120 bpm; PR interval abnormally high >220 milliseconds (ms): QRS interval abnormally high >=120 ms; QT corrected (Fridericia QTcF) categories; borderline prolonged QTc interval <450 to <=480 ms), prolonged QTc interval <480 to <=500 ms) and pathologically prolonged QTc interval >500 ms). Safety analysis set included all participants who received at least one dose of study intervention. Participants were analysed according to the study intervention they actually received.
    End point type
    Secondary
    End point timeframe
    IP: From Day 1 up to end of IP (up to Week 36 per PA 5; up to Week 52 prior to PA 5); CP: CP Week 1 up to CP Week 12; FU phase: FU Week 1 up to FU Week 48
    End point values
    IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    27
    8
    19
    25
    7
    17
    26
    8
    17
    Units: participants
    0
    0
    0
    0
    0
    0
    0
    0
    0
    No statistical analyses for this end point

    Secondary: Number of Participants With Worst Treatment-emergent Abnormalities in Vital Signs

    Close Top of page
    End point title
    Number of Participants With Worst Treatment-emergent Abnormalities in Vital Signs
    End point description
    Number of participants with worst treatment-emergent abnormalities in vital signs were reported. Treatment-emergent abnormality was defined as the abnormalities that were worsened as compared to the abnormality at baseline; which also included the shift from abnormally high to abnormally low and vice-versa. Abnormalities in vital signs included abnormal pulse rate (PR); abnormally low, <=45 bpm and abnormally high >=120 bpm; diastolic blood pressure (DBP) abnormally low <=50 mmHg, systolic blood pressure (SBP) abnormally low <=90 mmHg. Additionally, abnormal low SBP and DBP were <=50 mmHg and <+90 mmHg. Only those categories in which at least one participant had data were reported.
    End point type
    Secondary
    End point timeframe
    IP: From Day 1 up to end of IP (up to Week 36 per PA 5; up to Week 52 prior to PA 5); CP: CP Week 1 up to CP Week 12; FU phase: FU Week 1 up to FU Week 48
    End point values
    IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    26
    8
    19
    25
    7
    17
    26
    8
    17
    Units: participants
        DBP: High:
    3
    1
    1
    1
    0
    1
    1
    1
    0
        SBP: Low
    0
    1
    0
    1
    1
    1
    1
    0
    0
        SBP: High
    2
    1
    3
    1
    0
    0
    2
    1
    1
        Pulse rate: High
    0
    1
    0
    0
    0
    1
    0
    0
    0
    No statistical analyses for this end point

    Secondary: Number of Participants With Clinically Important Abnormalities in Physical Examination

    Close Top of page
    End point title
    Number of Participants With Clinically Important Abnormalities in Physical Examination
    End point description
    Number of participants with clinically important abnormalities in physical examination were reported. Safety analysis was based on safety analysis set which included all participants who received at least one dose of study intervention and were analysed according to the study intervention they actually received.
    End point type
    Secondary
    End point timeframe
    IP: From Day 1 up to end of IP (up to Week 36 per PA 5; up to Week 52 prior to PA 5); CP: CP Week 1 up to CP Week 12; FU phase: FU Week 1 up to FU Week 48
    End point values
    IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    27
    8
    19
    25
    7
    17
    26
    8
    17
    Units: participants
    0
    0
    0
    0
    0
    0
    0
    0
    0
    No statistical analyses for this end point

    Secondary: Percentage of Participants Who Reached HBsAg Less Than (<) 10 (International Units Per Milliliter [IU/mL]) at the End of the Induction Phase (EOI)

    Close Top of page
    End point title
    Percentage of Participants Who Reached HBsAg Less Than (<) 10 (International Units Per Milliliter [IU/mL]) at the End of the Induction Phase (EOI)
    End point description
    Percentage of participants who reached HBsAg <10 IU/mL at the end induction phase were reported. Treated analysis set included all participants who received at least 1 dose of study treatment within this Intervention-specific appendix (ISA). Here, "n"(number analysed) signifies participants who were evaluable at specified timepoints. Data for this endpoint were planned to be collected and analysed for IP only. Here, 99999 signifies that no participant was available for the analysis.
    End point type
    Secondary
    End point timeframe
    At IP Week 36 and EOI; anytime up to IP Week 36 (after PA 5) or up to IP Week 52 (prior to PA 5)
    End point values
    IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a
    Number of subjects analysed
    26
    7
    19
    Units: percentage of participants
    number (not applicable)
        IP Week 36 (n=13, 0, 1)
    0
    99999
    10
        End of Induction phase (n=26, 7, 19)
    15.4
    37.5
    10.5
    No statistical analyses for this end point

    Secondary: Time to Achieve First Occurrence of HBsAg <10 IU/mL

    Close Top of page
    End point title
    Time to Achieve First Occurrence of HBsAg <10 IU/mL
    End point description
    Time to achieve first occurrence of HBsAg <10 IU/mL]) were reported. Time to HBsAg <10 IU/mL was defined as the number of days between the date of first study treatment intake and the date of the first occurrence of HBsAg <10 IU/mL. Kaplan-Meier method was used for the estimation. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here, 99999 signifies that upper limit and lower limit of CI was not estimable due to insufficient number of participants with events.
    End point type
    Secondary
    End point timeframe
    From Baseline (Day 1 of IP) to Follow up Week 48
    End point values
    Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a
    Number of subjects analysed
    27
    8
    19
    Units: weeks
        median (confidence interval 90%)
    48.1 (-99999 to 99999)
    84.3 (2.1 to 99999)
    48.3 (36.1 to 99999)
    No statistical analyses for this end point

    Secondary: FU Phase: Percentage of Participants With HBsAg Seroclearance 48 Weeks After Stopping All Study Interventions of the Consolidation Phase and Without Restarting NA Treatment During Follow up Phase

    Close Top of page
    End point title
    FU Phase: Percentage of Participants With HBsAg Seroclearance 48 Weeks After Stopping All Study Interventions of the Consolidation Phase and Without Restarting NA Treatment During Follow up Phase
    End point description
    Percentage of participants with HBsAg seroclearance 48 weeks after stopping all study interventions at the consolidation phase and without restarting NA treatment during follow up phase were reported. HBsAg seroclearance was defined as (quantitative) HBsAg < LLOQ (HBsAg 0.05 IU/mL). Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    FU phase Week 48
    End point values
    FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    26
    6
    17
    Units: percentage of participants
        number (not applicable)
    11.5
    16.7
    11.8
    No statistical analyses for this end point

    Secondary: FU Phase: Percentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <LLOQ 48 Weeks After Stopping All Study Interventions of the Consolidation Phase and Without Restarting NA Treatment During Follow up Phase

    Close Top of page
    End point title
    FU Phase: Percentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <LLOQ 48 Weeks After Stopping All Study Interventions of the Consolidation Phase and Without Restarting NA Treatment During Follow up Phase
    End point description
    Percentage of participants with HBV DNA <LLOQ (<20 IU/mL) 48 weeks after stopping all study interventions of the consolidation phase and without restarting NA treatment during follow up phase were reported. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint. Here, N=0 signifies that data were not collected and analysed for participants who stopped NA at the end of treatment.
    End point type
    Secondary
    End point timeframe
    FU phase: FU Week 1 up to FU Week 48
    End point values
    FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    0 [6]
    0 [7]
    1
    Units: percentage of participants
        number (not applicable)
    0
    Notes
    [6] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment
    [7] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment
    No statistical analyses for this end point

    Secondary: Percentage of Participants Who Met Nucleos(t)Ide Analog (NA) Treatment Completion Criteria at the End of Consolidation Phase

    Close Top of page
    End point title
    Percentage of Participants Who Met Nucleos(t)Ide Analog (NA) Treatment Completion Criteria at the End of Consolidation Phase
    End point description
    Percentage of participants meeting the protocol-defined NA treatment completion criteria at EOC were reported. NA treatment completion criteria at CP Week 12 was defined as HBsAg <10 IU/mL; HBeAg-negative; HBV DNA <20 IU/mL, that is, lower limit of quantification (LLOQ); alanine aminotransferase(ALT) <3*ULN. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    At CP Week 12
    End point values
    CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    25
    7
    16
    Units: percentage of participants
        number (not applicable)
    0
    0
    5.9
    No statistical analyses for this end point

    Secondary: FU Phase: Number of Participants with Off-treatment Virologic HBV Flares During Follow up Phase

    Close Top of page
    End point title
    FU Phase: Number of Participants with Off-treatment Virologic HBV Flares During Follow up Phase
    End point description
    Number of participants with off-treatment virologic HBV flares were reported. Virologic flare was defined as confirmed HBV DNA >peak threshold (lowest peak to qualify as virologic flare was HBV DNA >200 IU/mL) in participants who were off-treatment and had HBV DNA <LLOQ (<20 IU/mL) at the last observed time point on all study treatments. The 3 thresholds of virologic flare was 20,000 IU/mL, 2,000 IU/mL and 200 IU/mL. Confirmed means that the criteria was fulfilled at 2 or more consecutive time points or at the last observed time point. Off-treatment was defined as the time period after stopping all study treatments (including NA). Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint. Here, N=0 signifies that data were not collected and analysed for participants who stopped NA at the end of treatment.
    End point type
    Secondary
    End point timeframe
    FU phase: FU Week 1 up to FU Week 48
    End point values
    FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    0 [8]
    0 [9]
    1
    Units: participants
    0
    Notes
    [8] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment
    [9] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment
    No statistical analyses for this end point

    Secondary: FU Phase: Number of Participants With On-treatment Biochemical Flares During Follow-up Phase

    Close Top of page
    End point title
    FU Phase: Number of Participants With On-treatment Biochemical Flares During Follow-up Phase
    End point description
    Number of participants with on-treatment biochemical HBV flares were reported. Biochemical flare was defined as first date of 2 consecutive visits with confirmed ALT and/or AST >=3*ULN and >=3*nadir (lowest value observed up to start of flare). Confirmed means that the criteria was fulfilled at 2 or more consecutive time points or at the last observed time point. On-treatment was defined as the time period during which the participant received any of the study drugs. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA.
    End point type
    Secondary
    End point timeframe
    FU phase: FU Week 1 up to FU Week 48
    End point values
    FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    26
    8
    17
    Units: participants
    2
    0
    2
    No statistical analyses for this end point

    Secondary: FU Phase: Number of Participants with Off-treatment Biochemical HBV Flares During Follow-up Phase

    Close Top of page
    End point title
    FU Phase: Number of Participants with Off-treatment Biochemical HBV Flares During Follow-up Phase
    End point description
    Number of participants with off-treatment biochemical HBV flares were reported. Biochemical flare was defined as first date of 2 consecutive visits with confirmed ALT and/or AST >=3*ULN and >=3*nadir (lowest value observed up to start of flare). Confirmed means that the criteria was fulfilled at 2 or more consecutive time points or at the last observed time point. Off-treatment was defined as the time period after stopping all study treatments (including NA). Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint. Here, N=0 signifies that data were not collected and analysed for participants who stopped NA at the end of treatment.
    End point type
    Secondary
    End point timeframe
    FU phase: FU Week 1 up to FU Week 48
    End point values
    FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    0 [10]
    0 [11]
    1
    Units: participants
    0
    Notes
    [10] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment
    [11] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment
    No statistical analyses for this end point

    Secondary: FU Phase: Number of Participants With Off-treatment Clinical Flares During Follow-up Phase

    Close Top of page
    End point title
    FU Phase: Number of Participants With Off-treatment Clinical Flares During Follow-up Phase
    End point description
    Clinical flares occurred either when a virologic flare (confirmed HBV DNA >peak threshold) & biochemical flare (ALT and/or AST >=3*ULN & >=3*nadir [lowest value observed during off-treatment period up to time point of meeting the flare criteria]) overlapped in time or when a biochemical flare started within 4 weeks following the end of a virologic flare. The HBV DNA thresholds were: 20,000 IU/mL, 2,000 IU/mL and 200 IU/mL. Confirmed means that criteria was fulfilled at 2 or more consecutive time points or at last observed time point. Off-treatment was defined as time period after stopping all study drugs (including NA). The start date of a clinical flare was minimum start date of virologic flare and biochemical flare. Treated analysis set was used. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint. Here, N=0 signifies that data were not collected and analysed for participants who stopped NA at the end of treatment.
    End point type
    Secondary
    End point timeframe
    FU phase: FU Week 1 up to FU Week 48
    End point values
    FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    0 [12]
    0 [13]
    1
    Units: participants
    0
    Notes
    [12] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment
    [13] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment
    No statistical analyses for this end point

    Secondary: FU Phase: Percentage of Participants Who Required NA Re-treatment During Follow-Up Phase

    Close Top of page
    End point title
    FU Phase: Percentage of Participants Who Required NA Re-treatment During Follow-Up Phase
    End point description
    Percentage of participants who required NA re-treatment during follow-up phase were reported. A responder was defined as a participant who met the criteria for NA re-treatment at any time during follow-up, for those participants who met the NA treatment completion criteria at any time during the study and actually stopped NA treatment. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint. Here, N=0 signifies that data were not collected and analysed for participants who stopped NA at the end of treatment.
    End point type
    Secondary
    End point timeframe
    FU phase: FU Week 1 up to FU Week 48
    End point values
    FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    0 [14]
    0 [15]
    1
    Units: percentage of participants
        number (not applicable)
    0
    Notes
    [14] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment
    [15] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment
    No statistical analyses for this end point

    Secondary: FU phase: Percentage of Participants Who Achieved Reduction (Sustained) in HBsAg Response (Per Definition 1) at Follow-up Week 48

    Close Top of page
    End point title
    FU phase: Percentage of Participants Who Achieved Reduction (Sustained) in HBsAg Response (Per Definition 1) at Follow-up Week 48
    End point description
    Percentage of participants with sustained (reduction) HBsAg response (per Definition 1) were reported. Sustained HBsAg response (definition 1) was defined as: For participants with FU Week 48 data: participants who had a >1 log10 decline from baseline in HBsAg and HBsAg <000 IU/mL at FU Week 48. For participants without FU Week 48 data: participants who had a HBsAg decline from baseline of >2 log10 at FU Week 24 or >1.5 log10 at FU Week 36 (most recent value used) and had HBsAg <1000 IU/mL at the last available timepoint.
    End point type
    Secondary
    End point timeframe
    At FU Phase Week 48
    End point values
    FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    26
    7
    17
    Units: percentage of participants
        number (not applicable)
    53.85
    57.1
    70.6
    No statistical analyses for this end point

    Secondary: Percentage of Participants Who Achieved Reduction (Sustained) in HBsAg Response (Per Definition 3) at Follow-up Week 48

    Close Top of page
    End point title
    Percentage of Participants Who Achieved Reduction (Sustained) in HBsAg Response (Per Definition 3) at Follow-up Week 48
    End point description
    Percentage of participants with sustained (reduction) HBsAg response (per definition 3) were reported. Sustained HBsAg response (per Definition 3) was defined as: for participants with a >1 log decline in HBsAg from baseline at last follow-up visit: Among the most recent three visits, the difference between log10 HBsAg at 2 of 3 last visit and 1 of 3 last visit was <0.2, and the difference between log10 HBsAg at 3 of 3 last visit and 1 of 3 last visit was <0.2 and had an HBsAg <1000 IU/mL at the last available timepoint. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    At Follow up Phase Week 48
    End point values
    FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    26
    7
    17
    Units: percentage of participants
        number (not applicable)
    42.3
    28.6
    52.9
    No statistical analyses for this end point

    Secondary: Percentage of Participants Who Achieved Reduction (Sustained) in HBsAg Response (Per Definition 2) at Follow-up Week 48

    Close Top of page
    End point title
    Percentage of Participants Who Achieved Reduction (Sustained) in HBsAg Response (Per Definition 2) at Follow-up Week 48
    End point description
    Percentage of participants with sustained (reduction) HBsAg response (per Definition 2) were reported. Sustained HBsAg response (per Definition 2) was defined as: for participants with a >1 log decline in HBsAg from baseline at last follow-up visit: Among the most recent three visits, the difference between log10 HBsAg at 2 of 3 last visit and 1 of 3 last visit was <0.2, and the difference between log10 HBsAg at 3 of 3 last visit and 1 of 3 last visit was <0.2. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    At FU Phase Week 48
    End point values
    FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    26
    7
    17
    Units: percentage of participants
        number (not applicable)
    65.4
    42.9
    70.6
    No statistical analyses for this end point

    Secondary: Percentage of Participants Who Achieved Reduction (Sustained) in HBsAg Response (Per Definition 4) at Follow-up Week 48

    Close Top of page
    End point title
    Percentage of Participants Who Achieved Reduction (Sustained) in HBsAg Response (Per Definition 4) at Follow-up Week 48
    End point description
    Percentage of participants with sustained (reduction) HBsAg response per Definition 4 were reported. Sustained HBsAg response (per Definition 4) was defined as stable level, decreasing level, and increasing level. Stable level: when HBsAg change from consolidationweek 12 to last available follow-up timepoint was within 0.2 log10. Decreasing level: when HBsAg change from consolidation week 12 to last available follow-up timepoint was less than -0.2 log10. Increasing level: when HBsAg change from consolidation week 12 to last available follow-up timepoint was more than 0.2 log10. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    At Follow up Phase Week 48
    End point values
    FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    26
    7
    17
    Units: percentage of participants
    number (not applicable)
        Stable: within +/-0.2 log10 IU/mL
    0
    14.3
    11.8
        Decreased: <0.2 log10 IU/mL
    19.2
    14.3
    17.6
        Increased: > +0.2 log10 IU/mL
    76.9
    71.4
    70.6
    No statistical analyses for this end point

    Secondary: Percentage of Participants With HBsAg Seroclearance at Follow-up Week 48

    Close Top of page
    End point title
    Percentage of Participants With HBsAg Seroclearance at Follow-up Week 48
    End point description
    Percentage of Participants with HBsAg Seroclearance were reported. HBsAg seroclearance was defined as (quantitative) HBsAg level <LLOQ (<0.05 IU/mL). Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    At Follow up Week 48
    End point values
    FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    26
    6
    17
    Units: percentage of participants
        number (not applicable)
    11.5
    16.7
    11.8
    No statistical analyses for this end point

    Secondary: Percentage of Participants with HBeAg Seroclearance at Follow-up Week 48

    Close Top of page
    End point title
    Percentage of Participants with HBeAg Seroclearance at Follow-up Week 48
    End point description
    Percentage of participants with HBeAg seroclearance were reported. HBeAg seroclearance was defined as (quantitative) HBeAg levels <LLOQ (<0.11 IU/mL). Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    At Follow up Week 48
    End point values
    FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    25
    6
    17
    Units: percentage of participants
        number (not applicable)
    28.0
    33.3
    17.6
    No statistical analyses for this end point

    Secondary: Percentage of Participants with HBsAg Seroconversion

    Close Top of page
    End point title
    Percentage of Participants with HBsAg Seroconversion
    End point description
    Seroconversion of HBsAg was defined as having achieved HBsAg seroclearance (defined as quantitative HBsAg <LLOQ [<0.05 IU/mL]) and appearance of anti-HBs antibodies (defined as a baseline anti-HBs antibodies [quantitative] <LLOQ [<5 milli-international units per milliliter (mIU/mL)] and a post-baseline assessment >=LLOQ [>=5 mIU/mL]). Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint and "n" (number analysed) signifies participants evaluable at specified timepoints and n=0, and 99999 signify that data were not collected and analysed as that timepoint was not applicable to the respective arm.
    End point type
    Secondary
    End point timeframe
    IP Week 24; CP: Week 12, FU phase: Week 48
    End point values
    IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    25
    7
    15
    24
    6
    15
    25
    7
    15
    Units: percentage of participants
    number (not applicable)
        IP: Week 24 (n=25, 7, 15, 0, 0, 0, 0, 0, 0)
    0
    0
    0
    99999
    99999
    99999
    99999
    99999
    99999
        CP: Week 12 (n=0, 0, 0, 24,6,15, 0, 0, 0)
    99999
    99999
    99999
    8.3
    33.3
    6.7
    99999
    99999
    99999
        FU phase Week 48 (n=0, 0, 0, 0, 0, 0, 25, 7, 15)
    99999
    99999
    99999
    99999
    99999
    99999
    12.0
    99999
    6.7
    No statistical analyses for this end point

    Secondary: Percentage of Participants with HBeAg Seroconversion

    Close Top of page
    End point title
    Percentage of Participants with HBeAg Seroconversion
    End point description
    Percentage of participants with HBeAg seroconversion were reported. Seroconversion of HBeAg was defined as having achieved HBeAg seroclearance (defined as [quantitative] HBeAg <LLOQ [<0.11 IU/mL]) together with appearance of anti-HBe antibodies (defined as a baseline anti-HBe antibodies [qualitative] with a "negative" result and a post-baseline assessment with “positive” result). Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Data were planned to be collected and analysed for CP and FU phase only. Here, n=0, and 99999 signify that data were not collected and analysed as that timepoint was not applicable to the respective arm.
    End point type
    Secondary
    End point timeframe
    CP: Week 12; FU phase: FU Week 48
    End point values
    CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    21
    6
    11
    22
    7
    11
    Units: percentage of participants
    number (not applicable)
        CP: Week 12 (n=21, 6,11, 0, 0, 0)
    0
    16.7
    9.1
    99999
    99999
    99999
        FU phase week 48 (n=0, 0, 0, 22, 7, 11)
    99999
    99999
    99999
    18.2
    20.0
    27.3
    No statistical analyses for this end point

    Secondary: Change from baseline over time in HBsAg Levels

    Close Top of page
    End point title
    Change from baseline over time in HBsAg Levels
    End point description
    Change from baseline over time in HBsAg levels at specified timepoints were reported. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "n"(number analysed) signifies participants evaluable at specified timepoints. Here, 99999 at IP Week 36 category for Cohort 2 (Per PA 6) signifies that standard deviation was not estimable as only 1 participant was analysed. Here, n=0, and 99999 signify that data were not collected and analysed as that timepoint was not applicable to the respective arm.
    End point type
    Secondary
    End point timeframe
    Baseline (Day 1 of IP), IP: Week 36; CP: Week 12; FU phase: Week 48
    End point values
    IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    27
    8
    19
    25
    7
    17
    26
    6
    17
    Units: log10 IU/mL
    arithmetic mean (standard error)
        IP: Week 36 (n=13,0,1,0,0,0,0,0,0)
    -2.29 ( 0.211 )
    99999 ( 99999 )
    -4.08 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CP: Week 12(n=0,0,0,25,7,17,0,0,0)
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    -3.51 ( 0.275 )
    -4.17 ( 0.444 )
    -3.53 ( 0.285 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        FU phase: Week 48(n=0,0,0,0,0,0,26,8,17)
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    -2.41 ( 0.364 )
    -3.14 ( 0.747 )
    -2.82 ( 0.425 )
    No statistical analyses for this end point

    Secondary: Change from baseline over time in HBeAg Levels

    Close Top of page
    End point title
    Change from baseline over time in HBeAg Levels
    End point description
    Change from baseline over time in HBeAg levels were reported. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this outcome measure and "n"(number analysed) signifies participants evaluable at specified timepoints. Here, 99999 at IP Week 36 category for Cohort 2 (Per PA 6) signifies that standard deviation was not estimable as only 1 participant was analysed. Here, "n"=number of subjects analysed at specified categories n=0, and 99999 signify that data were not collected and analysed as that timepoint was not applicable to the respective arm.
    End point type
    Secondary
    End point timeframe
    Baseline (Day 1 of IP), IP: Week 36; CP: Week 12; FU phase: Week 48
    End point values
    IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    27
    8
    19
    24
    7
    17
    25
    8
    17
    Units: log10 IU/mL
    arithmetic mean (standard error)
        IP: Week 36(n=12,0,1,0,0,0,0,0,0)
    -1.66 ( 0.159 )
    99999 ( 99999 )
    -2.85 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CP: Week 12(n=0,0,0,24,7,17,0,0,0)
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    -2.14 ( 0.146 )
    -2.39 ( 0.162 )
    -2.22 ( 0.234 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        FU phase: Week 48(n=0,0,0,0,0,0,25,8,17)
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    -2.45 ( 0.243 )
    -2.59 ( 0.508 )
    -2.47 ( 0.278 )
    No statistical analyses for this end point

    Secondary: Change from Baseline Over Time in HBV DNA Levels

    Close Top of page
    End point title
    Change from Baseline Over Time in HBV DNA Levels
    End point description
    Change from baseline over time in HBV DNA Levels were reported. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this outcome measure and "n"(number analysed) signifies participants evaluable at specified timepoints. Here, 99999 at IP Week 36 category for Cohort 2 (Per PA 6) signifies that standard deviation was not estimable as only 1 participant was analysed. Here, "n"=number of subjects analysed at specified categories and n=0, and 99999 signify that data were not collected and analysed as that timepoint was not applicable to the respective arm.
    End point type
    Secondary
    End point timeframe
    Baseline (Day 1 of IP), IP: Week 36; CP: Week 12; FU phase: Week 48
    End point values
    IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    27
    8
    19
    25
    6
    17
    26
    8
    17
    Units: log10 IU/mL
    arithmetic mean (standard error)
        IP: Week 36 (n=14,0,1,0,0,0,0,0,0)
    -5.84 ( 0.427 )
    99999 ( 99999 )
    -6.99 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CP: Week 12(n=0,0,0,25,6,17,0,0,0)
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    -6.29 ( 0.205 )
    -6.30 ( 0.350 )
    -6.07 ( 0.269 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        FU phase: Week 48(n=0,0,0,0,0,0,26,6,17)
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    -6.79 ( 0.203 )
    -5.95 ( 0.563 )
    -6.70 ( 0.257 )
    No statistical analyses for this end point

    Secondary: Time to Achieve First HBsAg Seroclearance

    Close Top of page
    End point title
    Time to Achieve First HBsAg Seroclearance
    End point description
    Time to achieve first HBsAg seroclearance (defined as quantitative HBsAg <LLOQ; HBsAg <0.05 IU/mL) were reported. Time to HBsAg seroclearance was defined as the number of days between the date of first study intervention intake and the date of the first occurrence of HBsAg seroclearance. Kaplan-Meier method was used for the estimation. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint. Here, 99999 signifies that that median [90% CI] data were not estimable due to low number of events. Per planned analysis data for this outcome measure was analysed per pooled cohorts only.
    End point type
    Secondary
    End point timeframe
    From baseline (Day 1 of IP) to Follow up Week 48
    End point values
    Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a
    Number of subjects analysed
    27
    8
    19
    Units: weeks
        median (confidence interval 90%)
    99999 (99999 to 99999)
    99999 (6.1 to 99999)
    99999 (99999 to 99999)
    No statistical analyses for this end point

    Secondary: Time to Achieve First HBV DNA <LLOQ

    Close Top of page
    End point title
    Time to Achieve First HBV DNA <LLOQ
    End point description
    Time to achieve first occurrence of HBV DNA < LLOQ (<20 IU/mL) were reported. Time to first occurrence of the HBV DNA < LLOQ was defined as the number of days between the date of first study intervention intake and the date of the first occurrence of the HBV DNA < LLOQ. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint. Per planned analysis data for this outcome measure was analysed per pooled cohorts only. Here 99999 signifies upper interval of [90% CI] data were not estimable due to low number of events.
    End point type
    Secondary
    End point timeframe
    From baseline (Day 1 of IP) to Follow up Week 48
    End point values
    Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a
    Number of subjects analysed
    27
    8
    19
    Units: weeks
        median (confidence interval 90%)
    35.9 (28.1 to 52.1)
    53.3 (12.1 to 99999)
    38.1 (24.1 to 50.1)
    No statistical analyses for this end point

    Secondary: Time to Achieve First HBeAg Seroclearance

    Close Top of page
    End point title
    Time to Achieve First HBeAg Seroclearance
    End point description
    Time to achieve first occurrence of HBeAg seroclearance (HBeAg <LLOQ [<0.11 IU/mL]) were reported. Time to first occurrence of the HBeAg seroclearance was defined as the number of days between the date of first study intervention intake and the date of the first occurrence of the HBeAg seroclearance. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint. Per planned analysis data for this outcome measure was analysed per pooled cohorts only. Here, 99999 signifies that Median and upper interval of [90% CI] data were not estimable due to low number of events.
    End point type
    Secondary
    End point timeframe
    From baseline (Day 1 of IP) to Follow up Week 48
    End point values
    Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a
    Number of subjects analysed
    27
    8
    19
    Units: weeks
        median (confidence interval 90%)
    112 (96.1 to 99999)
    100.3 (48.0 to 99999)
    99999 (59.1 to 99999)
    No statistical analyses for this end point

    Secondary: Percentage of participants with HBeAg Levels Below Different Cut-offs

    Close Top of page
    End point title
    Percentage of participants with HBeAg Levels Below Different Cut-offs
    End point description
    Percentage of participants with HBeAg levels below different cut-offs were reported. The cut-offs for HBeAg levels were : <LLOQ (<0.11 IU/mL), < 1 IU/mL, < 10 IU/mL, <100 IU/mL. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed)signifies participants who were evaluable for this endpoint. Here, n=0, and 99999 signify that data were not collected and analysed as that timepoint was not applicable to the respective arm.
    End point type
    Secondary
    End point timeframe
    IP: Week 36, CP: Week 12; FU phase: Week 48
    End point values
    IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    26
    8
    19
    24
    7
    17
    25
    8
    17
    Units: percentage of participants
    number (not applicable)
        IP Week 36: <0.11 IU/mL(n=12,0,1,0,0,0,0,0,0)
    8.3
    99999
    0
    99999
    99999
    99999
    99999
    99999
    99999
        IP Week 36: <1 IU/mL (n=12,0,1,0,0,0,0,0,0)
    25.0
    99999
    0
    99999
    99999
    99999
    99999
    99999
    99999
        IP Week 36: <10 IU/mL(n=12,0,1,0,0,0,0,0,0)
    50.0
    99999
    100.0
    99999
    99999
    99999
    99999
    99999
    99999
        IP Week 36: <100 IU/mL(n=12,0,1,0,0,0,0,0,0)
    100.0
    99999
    100.0
    99999
    99999
    99999
    99999
    99999
    99999
        CP Week 12: <0.11 IU/mL (n=0, 0, 0,24,7,17,0,0,0)
    99999
    99999
    99999
    12.5
    14.3
    17.6
    99999
    99999
    99999
        CP Week 12: <1 IU/mL(n=0, 0, 0,24,7,17,0,0,0)
    99999
    99999
    99999
    37.5
    14.3
    47.1
    99999
    99999
    99999
        CP Week 12: <10 IU/mL(n=0, 0, 0,24,7,17,0,0,0)
    99999
    99999
    99999
    75.0
    100.0
    76.5
    99999
    99999
    99999
        CP Week 12: <100 IU/mL(n=0, 0, 0,24,7,17,0,0,0)
    99999
    99999
    99999
    95.8
    100.0
    94.1
    99999
    99999
    99999
        FU Week 48: <0.11 IU/mL (n=0, 0, 0,0,0,0,25,6,17)
    99999
    99999
    99999
    99999
    99999
    99999
    28.0
    33.3
    17.6
        FU Week 48: <1 IU/mL(n=0, 0, 0,0,0,0,25,6,17)
    99999
    99999
    99999
    99999
    99999
    99999
    44.0
    50.0
    52.9
        FU Week 48: <10 IU/mL(n=0, 0, 0,0,0,0,25,6,17)
    99999
    99999
    99999
    99999
    99999
    99999
    80.0
    83.3
    76.5
        FU Week 48: <100IU/mL(n=0, 0, 0,0,0,0,25,6,17)
    99999
    99999
    99999
    99999
    99999
    99999
    96.0
    100
    100
    No statistical analyses for this end point

    Secondary: Percentage of Participants With HBsAg Levels Below Different Cut-offs

    Close Top of page
    End point title
    Percentage of Participants With HBsAg Levels Below Different Cut-offs
    End point description
    Percentage of participants with HBsAg levels below different cut-offs were reported. The cut-offs for HBsAg level were: <LLOQ (<0.05 IU/mL), <1 IU/mL, <10 IU/mL, <100 IU/mL, <1000 IU/mL. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here, "n"=number of subjects analysed at specified categories. n=0, and 99999 signify that data were not collected and analysed as that timepoint was not applicable to the respective arm.
    End point type
    Secondary
    End point timeframe
    IP: Week 36, CP: Week 12; FU phase: Week 48
    End point values
    IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    27
    8
    19
    25
    7
    17
    26
    8
    17
    Units: percentage of participants
    number (not applicable)
        IP Week 36: <0.05 IU/mL(n=13,0,1,0,0,0,0,0,0)
    0
    99999
    0
    99999
    99999
    99999
    99999
    99999
    99999
        IP Week 36: <1 IU/mL(n=13,0,1,0,0,0,0,0,0)
    0
    99999
    0
    99999
    99999
    99999
    99999
    99999
    99999
        IP Week 36: <10 IU/mL(n=13,0,1,0,0,0,0,0,0)
    0
    99999
    100.0
    99999
    99999
    99999
    99999
    99999
    99999
        IP Week 36: <100 IU/mL(n=13,0,1,0,0,0,0,0,0)
    23.1
    99999
    100.0
    99999
    99999
    99999
    99999
    99999
    99999
        IP Week 36: <1000 IU/mL(n=13,0,1,0,0,00,0,0)
    69.2
    99999
    100.0
    99999
    99999
    99999
    99999
    99999
    99999
        CP Week 12: <0.05 IU/mL(n=0,0,0,25,7,17,0,0,0)
    99999
    99999
    99999
    8.0
    42.9
    5.9
    99999
    99999
    99999
        CP Week 12: <1 IU/mL(n=0,0,0,25,7,17,0,0,0)
    99999
    99999
    99999
    20.0
    42.9
    23.5
    99999
    99999
    99999
        CP Week 12: <10 IU/mL(n=0,0,0,25,7,17,0,0,0)
    99999
    99999
    99999
    40.0
    42.9
    47.1
    99999
    99999
    99999
        CP Week 12: <100 IU/mL(n=0,0,0,25,7,17,0,0,0)
    99999
    99999
    99999
    60.0
    71.4
    76.5
    99999
    99999
    99999
        CP Week 12: <1000 IU0/mL(n=0,0,0,25,7,17,0,0,0)
    99999
    99999
    99999
    100.0
    100.0
    94.1
    99999
    99999
    99999
        FU Week 48: <0.05 IU/mL(n=0,0,0,0,0,0,26,6,17)
    99999
    99999
    99999
    99999
    99999
    99999
    11.5
    16.7
    11.8
        FU Week 48: <1 IU/mL(n=0,0,0,0,0,0,26,6,17)
    99999
    99999
    99999
    99999
    99999
    99999
    11.5
    33.3
    17.6
        FU Week 48: <10 IU/mL(n=0,0,0,0,0,0,26,6,17)
    99999
    99999
    99999
    99999
    99999
    99999
    19.2
    50.0
    29.4
        FU Week 48: <100 IU/mL(n=0,0,0,0,0,0,26,6,17)
    99999
    99999
    99999
    99999
    99999
    99999
    26.9
    50.0
    47.1
        FU Week 48: <1000 IU/mL(n=0,0,0,0,0,0,26,6,17)
    99999
    99999
    99999
    99999
    99999
    99999
    57.7
    66.7
    76.5
    No statistical analyses for this end point

    Secondary: Percentage of Participants With HBV DNA Levels Below Different Cut-offs

    Close Top of page
    End point title
    Percentage of Participants With HBV DNA Levels Below Different Cut-offs
    End point description
    Percentage of participants with HBV DNA levels below cut-offs were reported. The cut-offs for HBV DNA were as follows: <LLOQ (<20 IU/mL) for target detected or not detected(Td and Nd), < LLOQ for target not detected (TNd), and < LLOQ for target detected (TD), <60 IU/mL, <100 IU/mL, <200 IU/mL, <1000 IU/mL, <2000 IU/mL, <20000 IU/mL. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here, "n"(number of participants analysed) signifies participants analysed at specified categories. Here, n=0, and 99999 signify that data were not collected and analysed as that timepoint was not applicable to the respective arm.
    End point type
    Secondary
    End point timeframe
    IP: Week 36; CP: Week 12; FU phase: Week 48
    End point values
    IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    14
    0 [16]
    1
    25
    6
    17
    26
    8
    17
    Units: percentage of participants
    number (not applicable)
        IP Week 36:<LLOQ Td & Nd (n=14,0,1, 0,0,0,0,0,0)
    42.9
    100.0
    99999
    99999
    99999
    99999
    99999
    99999
        IP Week 36:<LLOQ for TNd(n=14,0,1, 0,0,0,0,0,0)
    0
    0
    99999
    99999
    99999
    99999
    99999
    99999
        IP Week 36:<LLOQ for Td(14,0,1, 0,0,0,0,0,0)
    42.9
    100.0
    99999
    99999
    99999
    99999
    99999
    99999
        IP Week 36:<60 IU/mL(14,0,1, 0,0,0,0,0,0)
    64.3
    100.0
    99999
    99999
    99999
    99999
    99999
    99999
        IP Week 36:<100 IU/mL (14,0,1, 0,0,0,0,0,0)
    71.4
    100.0
    99999
    99999
    99999
    99999
    99999
    99999
        IP Week 36:<200 IU/mL (14,0,1, 0,0,0,0,0,0)
    78.6
    100.0
    99999
    99999
    99999
    99999
    99999
    99999
        IP Week 36:<1000 IU/mL(n=14,0,1, 0,0,0,0,0,0)
    92.9
    100.0
    99999
    99999
    99999
    99999
    99999
    99999
        IP Week 36:<2000 IU/mL(n=14,0,1, 0,0,0,0,0,0)
    92.9
    100.0
    99999
    99999
    99999
    99999
    99999
    99999
        IP Week 36:<20000 IU/mL(n=14,0,1, 0,0,0,0,0,0)
    92.9
    100.0
    99999
    99999
    99999
    99999
    99999
    99999
        CP Week 12:<LLOQ:Td & Nd(n=0,0,0,25,6,17,0,0,0)
    99999
    99999
    32.0
    33.3
    29.4
    99999
    99999
    99999
        CP Week 12:<LLOQ for TNd(n=0,0,0,25,6,17,0,0,0)
    99999
    99999
    0
    0
    0
    99999
    99999
    99999
        CP Week 12:<LLOQ for Td(n=0,0,0,25,6,17,0,0,0)
    99999
    99999
    32.0
    33.3
    29.4
    99999
    99999
    99999
        CP Week 12:<60 IU/mL(n=0,0,0,25,6,17,0,0,0)
    99999
    99999
    76.0
    50.0
    58.8
    99999
    99999
    99999
        CP Week 12:<100 IU/mL(n=0,0,0,25,6,17,0,0,0)
    99999
    99999
    92.0
    83.3
    64.7
    99999
    99999
    99999
        CP Week 12:<200 IU/mL(n=0,0,0,25,6,17,0,0,0)
    99999
    99999
    96.0
    83.3
    82.4
    99999
    99999
    99999
        CP Week 12:<1000 IU/mL(n=0,0,0,25,6,17,0,0,0)
    99999
    99999
    100.0
    100.0
    94.1
    99999
    99999
    99999
        CP Week 12:<2000 IU/mL(n=0,0,0,25,6,17,0,0,0)
    99999
    99999
    100.0
    100.0
    100.0
    99999
    99999
    99999
        CP Week 12:<20000 IU/mL(n=0,0,0,25,6,17,0,0,0)
    99999
    99999
    100.0
    100.0
    100.0
    99999
    99999
    99999
        FU Week 48:<LLOQ Td & Nd(n=0,0,0,0,0,0,26,6,17)
    99999
    99999
    99999
    99999
    99999
    84.6
    50.0
    88.2
        FU Week 48: <LLOQ for TNd (n=0,0,0,0,0,0,26,6,17)
    99999
    99999
    99999
    99999
    99999
    34.6
    16.7
    17.6
        FU Week 48:<LLOQ for Td(n=0,0,0,0,0,0,26,6,17)
    99999
    99999
    99999
    99999
    99999
    50.0
    33.3
    70.6
        FU Week 48:<60 IU/mL(n=0,0,0,0,0,0,26,6,17)
    99999
    99999
    99999
    99999
    99999
    92.3
    50.0
    94.1
        FU Week 48:<100 IU/mL(n=0,0,0,0,0,0,26,6,17)
    99999
    99999
    99999
    99999
    99999
    100.0
    66.7
    100.0
        FU Week 48:<200 IU/mL(n=0,0,0,0,0,0,26,6,17)
    99999
    99999
    99999
    99999
    99999
    100.0
    83.3
    100.0
        FU Week 48:<1000 IU/mL(n=0,0,0,0,0,0,26,6,17)
    99999
    99999
    99999
    99999
    99999
    100.0
    83.3
    100.0
        FU Week 48:<2000 IU/mL(n=0,0,0,0,0,0,26,6,17)
    99999
    99999
    99999
    99999
    99999
    100.0
    83.3
    100.0
        FU Week 48:<20000 IU/mL(n=0,0,0,0,0,0,26,6,17)
    99999
    99999
    99999
    99999
    99999
    100.0
    100.0
    100.0
    Notes
    [16] - No participant was available for the analysis.
    No statistical analyses for this end point

    Secondary: Percentage of Participants with Virologic Breakthrough

    Close Top of page
    End point title
    Percentage of Participants with Virologic Breakthrough
    End point description
    Percentage of participants with virologic breakthrough on treatment were reported. Virological breakthrough was defined as confirmed on-treatment HBV DNA increase by >1 log10 IU/mL from nadir level (lowest level reached during treatment) in participants who did not have on-treatment HBV DNA level < LLOQ (<20 IU/mL) or confirmed on-treatment HBV DNA level >200 IU/mL in participants who had on-treatment HBV DNA level <LLOQ of the HBV DNA assay. Confirmed HBV DNA increase/level means that the criterion was fulfilled at 2 or more consecutive time points or at the last observed on-treatment time point. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA.
    End point type
    Secondary
    End point timeframe
    IP: From Day 1 up to end of IP (up to Week 36 per PA 5; up to Week 52 prior to PA 5); CP: CP Week 1 up to CP Week 12; FU phase: FU Week 1 up to FU Week 48
    End point values
    IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    27
    8
    19
    25
    7
    17
    26
    8
    17
    Units: percentage of participants
        number (not applicable)
    3.7
    12.5
    0
    0
    0
    0
    0
    50.0
    0
    No statistical analyses for this end point

    Secondary: Percentage of Participants Who Reached HBV DNA Undetectability After Re-start of NA Treatment During Follow-up

    Close Top of page
    End point title
    Percentage of Participants Who Reached HBV DNA Undetectability After Re-start of NA Treatment During Follow-up
    End point description
    Percentage of participants who reached HBV DNA undetectability after re-start of NA treatment during follow-up were reported. Undetectability of HBV DNA was defined as HBV DNA<LLOQ that is <20 IU/mL. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    FU phase: FU Week 1 up to FU Week 48
    End point values
    FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Number of subjects analysed
    27
    8
    19
    Units: percentage of participants
        number (not applicable)
    0
    0
    0
    No statistical analyses for this end point

    Secondary: Maximum Observed Plasma Concentration (Cmax) of JNJ-73763989 (Molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924])

    Close Top of page
    End point title
    Maximum Observed Plasma Concentration (Cmax) of JNJ-73763989 (Molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924])
    End point description
    Cmax of JNJ-73763989 (molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924]) were reported. Noncompartmental analysis were conducted to analyze Cmax JNJ-73763989 and its molecules. Pharmacokinetics analysis set (PK): included participants who had received at least 1 dose of any of the study interventions and had at least 1 valid blood sample drawn for PK analysis. Data for this endpoint was planned to be collected and analysed as pooled cohort in induction phase and consolidation phase only.
    End point type
    Secondary
    End point timeframe
    IP : Predose (0 hour), post dose on 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours on IP Week 24; CP: Predose (0 hour), post dose on 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours on CP Week 8
    End point values
    Induction phase Consolidation phase
    Number of subjects analysed
    8
    6
    Units: nanogram per milliliters (ng/mL)
    arithmetic mean (standard deviation)
        JNJ-73763976
    1376 ( 1266 )
    700 ( 227 )
        JNJ-73763924
    279 ( 308 )
    135 ( 39.9 )
    No statistical analyses for this end point

    Secondary: Time to Reach the Maximum Observed Plasma Concentration (tmax) of JNJ-73763989 (molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924])

    Close Top of page
    End point title
    Time to Reach the Maximum Observed Plasma Concentration (tmax) of JNJ-73763989 (molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924])
    End point description
    Time to reach the maximum observed plasma concentration (tmax) of JNJ-73763989 (molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924]) were reported. Non-compartmental analysis were conducted to analyze tmax of JNJ-73763989 and its molecules. Pharmacokinetics analysis set (PK): included participants who have received at least 1 dose of any of the study interventions and had at least 1 valid blood sample drawn for PK analysis. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint. Data for this endpoint was planned to be collected and analysed as pooled cohort in induction phase and consolidation phase only.
    End point type
    Secondary
    End point timeframe
    IP : Predose (0 hour), post dose on 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours on IP Week 24; CP: Predose (0 hour), post dose on 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours on CP Week 8
    End point values
    Induction phase Consolidation phase
    Number of subjects analysed
    8
    6
    Units: hour
    median (full range (min-max))
        JNJ-73763976
    5.53 (2.50 to 6.00)
    3.99 (2.98 to 6.00)
        JNJ-73763924
    4.00 (0.50 to 5.73)
    2.99 (1.00 to 4.00)
    No statistical analyses for this end point

    Secondary: Plasma Concentration 24 Hours After Administration (C24h) of JNJ-73763989 (Molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924])

    Close Top of page
    End point title
    Plasma Concentration 24 Hours After Administration (C24h) of JNJ-73763989 (Molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924])
    End point description
    Plasma concentration 24 hours after administration (C24h) of JNJ-73763989 (molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924]) were reported. Non-compartmental analysis were conducted to analyze C24h of JNJ-73763989 and its molecules. Pharmacokinetics analysis set (PK): included participants who have received at least 1 dose of any of the study interventions and had at least 1 valid blood sample drawn for PK analysis. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint. Data for this endpoint was planned to be collected and analysed as pooled cohort in induction phase and consolidation phase only.
    End point type
    Secondary
    End point timeframe
    IP: 24 hours post dose on Week 24 visit; CP: 24 hours post dose on Week 8 visit
    End point values
    Induction phase Consolidation phase
    Number of subjects analysed
    7
    6
    Units: ng/mL
    arithmetic mean (standard deviation)
        JNJ-73763976
    315 ( 213 )
    381 ( 155 )
        JNJ-73763924
    36.9 ( 27.9 )
    54.7 ( 25.0 )
    No statistical analyses for this end point

    Secondary: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours [AUC (0- 24 hours)] of JNJ-73763989 (molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924])

    Close Top of page
    End point title
    Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours [AUC (0- 24 hours)] of JNJ-73763989 (molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924])
    End point description
    Area under the plasma concentration-time curve from time zero to 24hours (AUC0 to 24h) of JNJ-73763989 (molecules:JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924]) were reported. Non-compartmental analysis were conducted toanalyze AUC0 to 24h of JNJ-73763989 and its molecules. Pharmacokinetics analysis set (PK): included participants who have received at least 1 dose of any of the study interventions and had at least 1 valid blood sample drawn for PK analysis. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint. Data for this endpoint was planned to be collected and analysed as pooled cohort in induction phase and consolidation phase only.
    End point type
    Secondary
    End point timeframe
    IP: 24 hours post dose on Week 24 visit; CP: 24 hours post dose on Week 8 visit
    End point values
    Induction phase Consolidation phase
    Number of subjects analysed
    7
    6
    Units: nanograms*hour per milliliters (ng*h/mL)
    arithmetic mean (standard deviation)
        JNJ-73763976
    19109 ( 12482 )
    12219 ( 3499 )
        JNJ-73763924
    3089 ( 1964 )
    2117 ( 639 )
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    IP: From Day 1 up to end of IP (up to Week 36 per PA 5; up to Week 52 prior to PA 5); CP: CP Week 1 up to CP Week 12; FU phase: FU Week 1 up to FU Week 48
    Adverse event reporting additional description
    Safety analysis was based on safety analysis set which included all participants who received at least one dose of study intervention and were analysed according to the study intervention they actually received.
    Assessment type
    Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    26.1
    Reporting groups
    Reporting group title
    IP: Cohort 1-Per PA 5: JNJ-3989 + NA + PegIFN-alpha-2a
    Reporting group description
    Per PA 5, participants received JNJ-3989 200 mg SC injection for Q4W plus NA (TAD 245 mg/TAF 25 mg) tablets orally QD in IP for 36 weeks.

    Reporting group title
    IP: Cohort 1-prior PA5: JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a
    Reporting group description
    Prior to PA 5, participants received JNJ-3989 200 mg SC injection for Q4W + JNJ-6379 250 mg tablets orally QD plus NA (TAD 245 mg/TAF 25 mg) tablet orally QD in IP for a RGT duration for >=36-weeks to <=52-weeks.

    Reporting group title
    FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Reporting group description
    After completion of CP, all participants entered 48-Week FU phase and stopped treatment with JNJ-3989 plus NA (TAD 245 mg/TAF 25 mg) plus PegIFN-alpha2a. If NA treatment completion criteria was met at CP Week 12, NA treatment was stopped at FU Week 2, if NA treatment completion criteria was not met, NA (TAD 245 mg/TAF 25 mg) was continued till the end of FU phase.

    Reporting group title
    CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
    Reporting group description
    After completion of IP, participants entered in 12-week CP and received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD from CP Week 1 to 12 and PegIFN-alpha2a 180 mcg SC QW was added to their treatment regimen from IP Week 36 for 12 weeks.

    Reporting group title
    FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a
    Reporting group description
    After completion of CP, all participants entered 48-Week FU phase and stopped treatment with JNJ-3989 plus JNJ-6379 plus NA (TAD 245 mg/TAF 25 mg) plus PegIFN-alpha2a. If NA treatment completion criteria was met at CP Week 12 NA was stopped at FU W2, if NA treatment completion criteria was not met, NA (TAD 245 mg/TAF 25 mg) was continued till the end of FU phase.

    Reporting group title
    FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a
    Reporting group description
    After completion of CP, all participants entered 48-Week FU phase and stopped treatment with JNJ-3989 plus NA (TAD 245 mg/TAF 25 mg) plus PegIFN-alpha2a. If NA treatment completion criteria was met at CP Week 12, NA treatment was stopped at FU Week 2, if NA treatment completion criteria was not met, NA (TAD 245 mg/TAF 25 mg) was continued till the end of FU phase.

    Reporting group title
    CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a
    Reporting group description
    After completion of IP, participants entered in 12 week CP and received JNJ-3989 200 mg SC Q4W plus JNJ-6379 250 tablets QD plus NA (either TAD 250 mg or TAF 25 mg) tablet orally QD from CP Week 1 to 12 and PegIFN-alpha-2a 180 mcg SC injection was added to their treatment regimen from IP Week 36 for 12 weeks.

    Reporting group title
    IP: Cohort 2 - Per PA 6: JNJ-3989 + NA + PegIFN-alpha-2a
    Reporting group description
    Participants enrolled as per PA 6, received JNJ-3989 200 mg SC for Q4W plus NA (TAD 250 mg/TAF 25 mg) tablet orally QD in IP for 36 weeks.

    Reporting group title
    CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a
    Reporting group description
    After completion of IP, participants entered in 12-week CP and received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD from CP Week 1 to 12 and PegIFN-alpha2a 180 mcg SC QW was added to their treatment regimen from IP Week 36 for 12 weeks.

    Serious adverse events
    IP: Cohort 1-Per PA 5: JNJ-3989 + NA + PegIFN-alpha-2a IP: Cohort 1-prior PA5: JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a IP: Cohort 2 - Per PA 6: JNJ-3989 + NA + PegIFN-alpha-2a CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    1 / 17 (5.88%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         number of deaths (all causes)
    0
    0
    0
    0
    0
    0
    0
    0
    0
         number of deaths resulting from adverse events
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Pregnancy, puerperium and perinatal conditions
    Ectopic Pregnancy
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    1 / 17 (5.88%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    IP: Cohort 1-Per PA 5: JNJ-3989 + NA + PegIFN-alpha-2a IP: Cohort 1-prior PA5: JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a IP: Cohort 2 - Per PA 6: JNJ-3989 + NA + PegIFN-alpha-2a CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    8 / 8 (100.00%)
    19 / 27 (70.37%)
    11 / 17 (64.71%)
    13 / 17 (76.47%)
    15 / 26 (57.69%)
    5 / 8 (62.50%)
    21 / 25 (84.00%)
    15 / 19 (78.95%)
    7 / 7 (100.00%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Haemangioma of Liver
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    General disorders and administration site conditions
    Hyperthermia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    2 / 25 (8.00%)
    0 / 19 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    2
    0
    1
    Fatigue
         subjects affected / exposed
    2 / 8 (25.00%)
    1 / 27 (3.70%)
    0 / 17 (0.00%)
    4 / 17 (23.53%)
    0 / 26 (0.00%)
    1 / 8 (12.50%)
    5 / 25 (20.00%)
    2 / 19 (10.53%)
    2 / 7 (28.57%)
         occurrences all number
    3
    1
    0
    4
    0
    1
    5
    2
    2
    Chills
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    2 / 25 (8.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    2
    0
    0
    Asthenia
         subjects affected / exposed
    0 / 8 (0.00%)
    2 / 27 (7.41%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    1 / 25 (4.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    3
    0
    1
    0
    0
    2
    0
    0
    Injection Site Erythema
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    3 / 17 (17.65%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    3 / 25 (12.00%)
    1 / 19 (5.26%)
    1 / 7 (14.29%)
         occurrences all number
    1
    0
    0
    3
    0
    0
    13
    1
    1
    Injection Site Bruising
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    1 / 17 (5.88%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    1
    1
    0
    0
    0
    1
    0
    Influenza Like Illness
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    1 / 17 (5.88%)
    2 / 17 (11.76%)
    2 / 26 (7.69%)
    0 / 8 (0.00%)
    4 / 25 (16.00%)
    0 / 19 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    0
    1
    2
    2
    0
    6
    0
    1
    Injection Site Pain
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    1 / 25 (4.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    2
    0
    0
    0
    0
    0
    1
    0
    0
    Injection Site Pruritus
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    0
    0
    0
    Injection Site Rash
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    1 / 25 (4.00%)
    0 / 19 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    3
    0
    1
    Injection Site Reaction
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    2 / 25 (8.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    5
    0
    0
    2
    0
    0
    Injury Associated with Device
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Pyrexia
         subjects affected / exposed
    1 / 8 (12.50%)
    1 / 27 (3.70%)
    1 / 17 (5.88%)
    3 / 17 (17.65%)
    1 / 26 (3.85%)
    1 / 8 (12.50%)
    3 / 25 (12.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    1
    2
    1
    4
    2
    1
    3
    1
    0
    Pain
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    2 / 17 (11.76%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    0
    0
    0
    Non-Cardiac Chest Pain
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    1 / 25 (4.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    1
    0
    0
    Temperature Intolerance
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Immune system disorders
    Seasonal Allergy
         subjects affected / exposed
    2 / 8 (25.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    1 / 26 (3.85%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    3
    0
    0
    0
    1
    0
    0
    0
    0
    Mite Allergy
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Food Allergy
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    1 / 17 (5.88%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Reproductive system and breast disorders
    Vaginal Haemorrhage
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    1 / 17 (5.88%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    1
    0
    Respiratory, thoracic and mediastinal disorders
    Oropharyngeal Pain
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 27 (3.70%)
    2 / 17 (11.76%)
    0 / 17 (0.00%)
    1 / 26 (3.85%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    1
    4
    0
    1
    0
    0
    1
    0
    Epistaxis
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Dyspnoea Exertional
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    1
    Dry Throat
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Cough
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 27 (0.00%)
    2 / 17 (11.76%)
    0 / 17 (0.00%)
    2 / 26 (7.69%)
    1 / 8 (12.50%)
    0 / 25 (0.00%)
    2 / 19 (10.53%)
    1 / 7 (14.29%)
         occurrences all number
    1
    0
    4
    0
    2
    1
    0
    2
    1
    Allergic Sinusitis
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Dyspnoea
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Respiratory Tract Congestion
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Rhinitis Allergic
         subjects affected / exposed
    1 / 8 (12.50%)
    1 / 27 (3.70%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    0
    Rhinorrhoea
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    1 / 17 (5.88%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    1
    0
    Sinus Congestion
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    1 / 17 (5.88%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    1
    1
    0
    0
    0
    0
    0
    Productive Cough
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Psychiatric disorders
    Insomnia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    1 / 17 (5.88%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    1 / 8 (12.50%)
    1 / 25 (4.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    1
    1
    0
    0
    Depressed Mood
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    1 / 8 (12.50%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Apathy
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Anxiety Disorder
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    1
    0
    Investigations
    Alanine Aminotransferase Increased
         subjects affected / exposed
    0 / 8 (0.00%)
    8 / 27 (29.63%)
    1 / 17 (5.88%)
    4 / 17 (23.53%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    2 / 25 (8.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    13
    1
    6
    0
    0
    2
    3
    0
    Aspartate Aminotransferase Increased
         subjects affected / exposed
    0 / 8 (0.00%)
    2 / 27 (7.41%)
    0 / 17 (0.00%)
    2 / 17 (11.76%)
    0 / 26 (0.00%)
    1 / 8 (12.50%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    4
    0
    2
    0
    1
    0
    0
    1
    Blood Creatine Phosphokinase Increased
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Blood Alkaline Phosphatase Increased
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Blood Glucose Increased
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 27 (3.70%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    1 / 8 (12.50%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    1
    0
    0
    0
    Body Temperature Increased
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    2 / 25 (8.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    2
    0
    0
    Glucose Urine Present
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    1 / 8 (12.50%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    3
    0
    0
    0
    Liver Scan Abnormal
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Ultrasound Liver Abnormal
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    1 / 17 (5.88%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    White Blood Cell Count Decreased
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    2 / 25 (8.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    2
    0
    0
    Weight Decreased
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    1 / 25 (4.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    1
    0
    Neutrophil Count Decreased
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    2 / 25 (8.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    2
    0
    0
    Injury, poisoning and procedural complications
    Head Injury
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    1 / 17 (5.88%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Skin Wound
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    1 / 17 (5.88%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Skin Laceration
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 27 (3.70%)
    1 / 17 (5.88%)
    0 / 17 (0.00%)
    1 / 26 (3.85%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    1
    1
    0
    1
    0
    0
    0
    0
    Ligament Sprain
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Cardiac disorders
    Tachycardia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    1 / 8 (12.50%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Sinus Tachycardia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Palpitations
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Nervous system disorders
    Amnestic Disorder
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Neuropathy Peripheral
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    1 / 17 (5.88%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Headache
         subjects affected / exposed
    3 / 8 (37.50%)
    5 / 27 (18.52%)
    1 / 17 (5.88%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    1 / 8 (12.50%)
    5 / 25 (20.00%)
    2 / 19 (10.53%)
    0 / 7 (0.00%)
         occurrences all number
    3
    10
    2
    1
    0
    1
    6
    2
    0
    Dizziness Postural
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Blood and lymphatic system disorders
    Leukopenia
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    2 / 26 (7.69%)
    0 / 8 (0.00%)
    4 / 25 (16.00%)
    0 / 19 (0.00%)
    2 / 7 (28.57%)
         occurrences all number
    1
    0
    0
    0
    3
    0
    6
    0
    2
    Anaemia
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 27 (0.00%)
    1 / 17 (5.88%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    1 / 25 (4.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    1
    0
    0
    0
    1
    0
    0
    Neutropenia
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    1 / 26 (3.85%)
    0 / 8 (0.00%)
    7 / 25 (28.00%)
    0 / 19 (0.00%)
    2 / 7 (28.57%)
         occurrences all number
    1
    0
    0
    1
    1
    0
    12
    0
    3
    Thrombocytopenia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    1 / 25 (4.00%)
    0 / 19 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    1
    0
    1
    Ear and labyrinth disorders
    Ear Pain
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Eye disorders
    Cataract
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    0
    0
    0
    Conjunctival Hyperaemia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    1 / 17 (5.88%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Visual Impairment
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Myopia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Eye Pruritus
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 27 (3.70%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    2
    0
    Gastrointestinal disorders
    Abdominal Discomfort
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    0
    Aphthous Ulcer
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    1 / 17 (5.88%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    2
    0
    0
    0
    0
    1
    0
    Abdominal Pain Upper
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    1 / 26 (3.85%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    2 / 19 (10.53%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    1
    1
    0
    0
    2
    0
    Abdominal Pain Lower
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    1 / 17 (5.88%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Abdominal Pain
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    1 / 25 (4.00%)
    2 / 19 (10.53%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    1
    2
    0
    Abdominal Distension
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 27 (3.70%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    1
    0
    1
    0
    0
    0
    2
    0
    Constipation
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 27 (3.70%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    1
    0
    Dental Caries
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    1 / 25 (4.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    1
    0
    0
    Haemorrhoids
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Gastrooesophageal Reflux Disease
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    2 / 19 (10.53%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    2
    0
    Food Poisoning
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Dyspepsia
         subjects affected / exposed
    0 / 8 (0.00%)
    2 / 27 (7.41%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    1 / 26 (3.85%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    2
    0
    1
    1
    0
    0
    0
    0
    Diarrhoea
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    1 / 26 (3.85%)
    0 / 8 (0.00%)
    2 / 25 (8.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    0
    0
    2
    0
    2
    1
    0
    Large Intestine Polyp
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Nausea
         subjects affected / exposed
    3 / 8 (37.50%)
    4 / 27 (14.81%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    2 / 19 (10.53%)
    0 / 7 (0.00%)
         occurrences all number
    3
    4
    0
    0
    0
    0
    0
    2
    0
    Mouth Ulceration
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    1 / 17 (5.88%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Rectal Haemorrhage
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Vomiting
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Toothache
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    1
    0
    Skin and subcutaneous tissue disorders
    Eczema
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    1
    0
    Rash Maculo-Papular
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Skin Irritation
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Alopecia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    1 / 26 (3.85%)
    1 / 8 (12.50%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    0
    0
    0
    Skin Ulcer
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Renal and urinary disorders
    Dysuria
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Musculoskeletal and connective tissue disorders
    Pain in Extremity
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 27 (0.00%)
    1 / 17 (5.88%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    2 / 7 (28.57%)
         occurrences all number
    1
    0
    1
    1
    0
    0
    0
    1
    2
    Muscular Weakness
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 27 (3.70%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    1
    Muscle Spasms
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 27 (3.70%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    1 / 8 (12.50%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    1
    0
    0
    0
    Limb Mass
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Back Pain
         subjects affected / exposed
    1 / 8 (12.50%)
    2 / 27 (7.41%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    1 / 26 (3.85%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    2 / 19 (10.53%)
    0 / 7 (0.00%)
         occurrences all number
    1
    2
    0
    1
    1
    0
    0
    2
    0
    Arthralgia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    1 / 17 (5.88%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    1 / 25 (4.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    1
    1
    0
    0
    13
    1
    0
    Myalgia
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 27 (3.70%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    2 / 25 (8.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    3
    1
    0
    Infections and infestations
    Aspergilloma
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Acarodermatitis
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Lower Respiratory Tract Infection
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Carbuncle
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Conjunctivitis
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 27 (3.70%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    0
    1
    0
    0
    0
    1
    1
    Covid-19
         subjects affected / exposed
    2 / 8 (25.00%)
    2 / 27 (7.41%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    7 / 26 (26.92%)
    1 / 8 (12.50%)
    3 / 25 (12.00%)
    4 / 19 (21.05%)
    0 / 7 (0.00%)
         occurrences all number
    2
    2
    0
    0
    7
    1
    3
    4
    0
    Hepatitis B
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Influenza
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 27 (3.70%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    1
    0
    1
    0
    0
    0
    1
    0
    Lower Respiratory Tract Infection Viral
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Nasopharyngitis
         subjects affected / exposed
    0 / 8 (0.00%)
    2 / 27 (7.41%)
    2 / 17 (11.76%)
    0 / 17 (0.00%)
    4 / 26 (15.38%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    2
    2
    0
    5
    0
    0
    0
    0
    Oral Herpes
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Paronychia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    1 / 17 (5.88%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Periodontitis
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    1 / 17 (5.88%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Respiratory Tract Infection
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    1 / 17 (5.88%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    0
    Urinary Tract Infection
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    2 / 8 (25.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    2
    0
    1
    0
    Viral Infection
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    1 / 8 (12.50%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Respiratory Tract Infection Viral
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Upper Respiratory Tract Infection
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 27 (3.70%)
    1 / 17 (5.88%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    2 / 19 (10.53%)
    0 / 7 (0.00%)
         occurrences all number
    0
    1
    3
    0
    0
    0
    0
    3
    0
    Sinusitis
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    1 / 17 (5.88%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Rhinitis
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    1 / 17 (5.88%)
    1 / 17 (5.88%)
    1 / 26 (3.85%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    1 / 19 (5.26%)
    1 / 7 (14.29%)
         occurrences all number
    0
    0
    1
    1
    1
    0
    0
    1
    1
    Metabolism and nutrition disorders
    Decreased Appetite
         subjects affected / exposed
    0 / 8 (0.00%)
    2 / 27 (7.41%)
    0 / 17 (0.00%)
    2 / 17 (11.76%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    1 / 25 (4.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    2
    0
    2
    0
    0
    1
    0
    0
    Iron Deficiency
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    0 / 17 (0.00%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    1 / 8 (12.50%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Vitamin B12 Deficiency
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 27 (0.00%)
    1 / 17 (5.88%)
    0 / 17 (0.00%)
    0 / 26 (0.00%)
    0 / 8 (0.00%)
    0 / 25 (0.00%)
    0 / 19 (0.00%)
    0 / 7 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    30 Jul 2021
    Amendment 5: The purpose for this amendment was a change in study treatment regimens, based on the availability of preliminary 48-week treatment data from the Phase 2b study REEF-1 (73763989HPB2001), and new data presented during the European Association for the Study of the Liver (EASL) conference of 2021 showing that HBsAg declines with siRNA treatment can be increased when combined with PegIFN.
    30 Sep 2021
    Amendment 6: The purpose for this amendment was to remove JNJ-6379 as study intervention, to add a new nucleos(t)ide analog (NA) re-treatment criterion for subjects who discontinued NA treatment during follow-up, and to include more frequent monitoring for subjects who discontinued NA treatment during follow-up.
    25 Nov 2021
    Amendment 7: The purpose of amendment was to update the criteria for post-treatment monitoring and for nucleos(t)ide analog (NA) re-treatment for participants who discontinued NA treatment during follow-up.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 09:52:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA